Jump to content

Tumor Anti Angiogenesis

From mintOC
Tumor Anti Angiogenesis
State dimension: 1
Differential states: 3
Discrete control functions: 1


The tumor anti-angiogenesis problem is a classical benchmark in biomedical optimal control.

It is based on the mathematical model of Hahnfeldt et al. [1] for tumor growth under angiogenic signalling, as studied from an optimal control perspective by Ledzewicz and Schättler [2]. Angiogenesis is the process by which tumors recruit a network of blood vessels to sustain their growth; anti-angiogenic therapy targets this process by administering inhibitor agents. The two biological states are the tumor volume and the carrying capacity of the vascular endothelium (which sets the maximum supportable tumor size). A third state tracks the cumulative inhibitor dose, enforcing a total-dose constraint. The control is the instantaneous inhibitor dose rate. The final time is free and is itself an optimization variable, bounded within a physiologically reasonable range. The objective is to minimise the tumor volume at the final time. The problem is known to exhibit a rich optimal control structure, including bang–bang arcs, singular arcs, and boundary arcs corresponding to the dose constraint.

Mathematical formulation

minu,tfp(tf)subject top˙(t)=−ξp(t)ln⁡(p(t)q(t)),q˙(t)=(b−μ−dp(t)2/3−Gu(t))q(t),y˙(t)=u(t),(p(0),q(0),y(0))=(p0,q0,0),y(tf)≤A,u(t)∈[0,umax]∀t∈[0,tf],tf∈[0.5,2.0],

where p(t) is the tumor volume (mm3), q(t) is the endothelial carrying capacity (mm3), and y(t) is the cumulative inhibitor dose (mg/kg) administered up to time t. The tumor dynamics follow the Gompertz law p˙=−ξpln⁡(p/q), which models logistic-like growth bounded by the carrying capacity q. The carrying capacity evolves through a balance of self-stimulation (bq), natural endothelial cell loss (μq), inhibition proportional to tumor surface area (dp2/3q), and drug-induced endothelial loss (Guq). The state y(t) enforces the total-dose constraint y(tf)≤A as an isoperimetric inequality. The terminal time tf is a free optimization variable.

Parameters

These fixed values are used within the model:

Symbol Value Description
ξ 0.084 Tumor growth rate (day−1)
b 5.85 Endothelial self-stimulation rate (day−1)
μ 0 Natural endothelial cell loss rate (day−1)
d 0.00873 Angiogenic inhibition coefficient (mm−2 day−1)
G 0.15 Drug efficacy on endothelium (kg mg−1 day−1)
umax 75 Maximum inhibitor dose rate (mg kg−1 day−1)
A 75 Maximum cumulative inhibitor dose (mg kg−1)
p0 12000 Initial tumor volume (mm3)
q0 15000 Initial endothelial carrying capacity (mm3)
tf free Terminal time, optimized in [0.5, 2.0] (days)

Reference Solutions

Here is one local solution to the above control problem.

Miscellaneous and Further Reading

The equilibrium p*=q* corresponds to a tumor at maximum sustainable size. Without treatment, p(t) converges to this steady state. Ledzewicz and Schättler [2] characterise the optimal control using Pontryagin's minimum principle and show that the optimal policy consists of a sequence of full-dose (u=umax), no-dose (u=0), and singular arcs, depending on the initial conditions and remaining dose budget. The problem is included in the GPOPS-II benchmark suite [3].

References

[1] Hahnfeldt, P., Panigrahy, D., Folkman, J., & Hlatky, L. (1999). Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Research, 59(19), 4770–4775.
[2] Ledzewicz, U., & Schättler, H. (2007). Antiangiogenic therapy in cancer treatment as an optimal control problem. SIAM Journal on Control and Optimization, 46(3), 1052–1079.
[3] Patterson, M. A., & Rao, A. V. (2014). GPOPS-II: A MATLAB software for solving multiple-phase optimal control problems using hp-adaptive Gaussian quadrature collocation methods and sparse nonlinear programming. ACM Transactions on Mathematical Software, 41(1), 1.